Enhancing diabetes therapy with pH-sensitive co-delivery of metformin hydrochloride and glipizide using MCM-48-based dual drug delivery system.

Monotherapy in diabetes management is losing interest due to its ineffectiveness in achieving optimal glycaemic control in a significant proportion of diabetic patients. Therefore, combined therapy is increasingly preferred by clinicians, which offers enhanced effectiveness and a better safety profile for managing the condition. The present work deals with the designing of a dual drug nanocarrier based on MCM-48 and 12-tungtophosphoric acid (TPA) for the co-delivery of Glipizide (GLP) and Metformin Hydrochloride (MTF) as well as its characterization using various techniques.

Nickel salt of phosphomolybdic acid as a bi-functional homogeneous recyclable catalyst for base free transformation of aldehyde into ester.

A Ni salt of phosphomolybdic acid (NiHPMA) was synthesized and characterized by various physico-chemical techniques such as EDX, UV-Visible spectroscopy, FT-IR, Raman spectroscopy and XPS. FT-IR and Raman spectroscopy confirm the presence of Ni as a counter cation while UV-Visible and XPS studies to confirm the presence of Ni(ii) in the catalyst. The catalyst was evaluated for its bi-functional activity towards the tandem conversion of benzaldehyde to ethyl benzoate and it was found that very small amounts of Ni (2.